Fibroblast Growth Factor-23 in Early Chronic Kidney Disease | Zendy

Pieter Evenepoel | Zendy; Björn Meijers | Zendy; Liesbeth Viaene | Zendy; Bert Bammens | Zendy; Kathleen Claes | Zendy; Dirk Kuypers | Zendy; Dirk Vanderschueren | Zendy; Yves Vanrenterghem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fibroblast Growth Factor-23 in Early Chronic Kidney Disease

Author(s) -

Pieter Evenepoel,

Björn Meijers,

Liesbeth Viaene,

Bert Bammens,

Kathleen Claes,

Dirk Kuypers,

Dirk Vanderschueren,

Yves Vanrenterghem

Publication year - 2010

Publication title -

clinical journal of the american society of nephrology

Language(s) - Uncategorized

Resource type - Journals

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.08241109

Subject(s) - fibroblast growth factor 23 , secondary hyperparathyroidism , medicine , parathyroid hormone , endocrinology , kidney disease , excretion , pathogenesis , renal function , hyperparathyroidism , phosphate , hyperphosphatemia , calcium , chemistry , biochemistry

The discovery of fibroblast growth factor-23 (FGF-23) and the elucidation of its function as a phosphaturic and 1,25(OH)2VitD counter-regulatory hormone provides a new conceptual framework for the understanding of the pathogenesis of secondary hyperparathyroidism. This study aims to elucidate the complex associations between FGF-23, parathyroid hormone (PTH), 1,25(OH)2D, and phosphate in patients with early-stage chronic kidney disease (CKD) and to provide clinical evidence in favor of the new phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research